In the MAGPIE trial, magnesium sulfate was compared to placebo in pre-eclamptic women. The primary outcome demonstrated a reduction in which complication, forming the current evidence base for magnesium prophylaxis?

• A Maternal stroke
• B Fetal growth restriction
• C Preterm delivery
• D Eclampsia ✓

Explanation

The MAGPIE trial (Magnesium Sulphate for Prevention of Eclampsia, Lancet 2002) enrolled over 10,000 women and demonstrated that magnesium sulfate halved the risk of eclampsia compared to placebo (RR 0.58). This landmark RCT is the evidence base for universal magnesium prophylaxis in women with severe pre-eclampsia. It did not demonstrate statistically significant reductions in maternal stroke or perinatal mortality as primary outcomes.

Reference: Williams Obstetrics, 26th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.